TTNP
Titan Pharmaceuticals, Inc.
Set alert
2.34 0.00 0.00%
2.30 Day range 2.69
3.14 52-week range 14.80
- YTD
- -28.22%
- 1 year
- -55.09%
- Open
- 2.55
- Prev close
- 2.34
- Mkt cap
- 2.96M
- Vol
- 131.90K
- Avg vol
- 18.01K
- EPS
- -6.64
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.30
- High
- 2.69
- Forward P/E
- -3.56
- Beta
- 1.13
- Short ratio
- 0.66
- Inst. own
- 1.85%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Dec 24, 2024
- 50-d avg
- 3.97
- 200-d avg
- 5.73
- 1y target
- 0.00
Key statistics
- Market cap
- 2.96M
- Enterprise value
- -1.00M
- Trailing P/E
- 0.00
- Forward P/E
- -3.56
- PEG ratio
- 0.00
- Price / sales
- 987.37
- Price / book
- 0.74
- EPS (TTM)
- -6.64
- Beta
- 1.13
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 3.00K
- Revenue growth
- 0.00%
- Free cash flow
- -5.21M
- Total cash
- 4.09M
- Total debt
- 0
- Return on equity
- -368.99%
- Shares outstanding
- 914.23K
- Short % of float
- 1.23%
- 50-day average
- 3.97
- 200-day average
- 5.73
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Dec 24, 2024
Expected Dec 24, 2024. Consensus EPS estimate 0.00.
Financials — quick view
TTNP Revenue — quarterly 0
TTNP Net income — quarterly -689.00K
TTNP EPS — quarterly -0.65
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 24, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Aug 15, 2024 | Jun 1, 2024 | 0.00 | -2.29 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -1.24 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -0.40 | — | — |
| Nov 14, 2022 | Sep 1, 2022 | 0.00 | — | — | — |
About Titan Pharmaceuticals, Inc.
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- titanpharm.com
News
- Titan Pharmaceuticals, Inc. Announces Closing of Merger with Black Titan Corporation
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- 12 Health Care Stocks Moving In Monday's After-Market Session
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- TITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc. - TTNP
- URGENT: The M&A Class Action Firm Encourages $hareholders to Act Before Vote – Titan Pharmaceuticals, Inc. (Nasdaq: TTNP)
- 12 Health Care Stocks Moving In Friday's Intraday Session
Your note
Sign in to keep a note on TTNP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BEN-TZVI AVRAHAM | Director | Stock Award(Grant) | Oct 24, 2023 | 66,250 |
| CHASEY PETER LOUIS | Director | Stock Award(Grant) | Jul 25, 2023 | 50,000 |
| CHOONG CHOON HAU | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Mar 17, 2024 | 3,802,100 |
| GREENBERG ERIC HOWARD | Director | Stock Award(Grant) | Oct 24, 2023 | 66,250 |
| LAZAR DAVID ELLIOT | Chief Executive Officer | Stock Award(Grant) | Jul 25, 2023 | 100,000 |
| MCMURDO MATTHEW CHARLES | Director | Stock Award(Grant) | Oct 24, 2023 | 66,250 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Renaissance Technologies, LLC | 1.21% | 11,066 | 35.85K | Sep 29, 2024 |
| UBS Group AG | 0.52% | 4,773 | 15.46K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.08% | 743 | 2.41K | Sep 29, 2024 |
| MCF Advisors LLC | 0.02% | 165 | 534 | Sep 29, 2024 |
| Global Wealth Strategies & Associates | 0.00% | 2 | 6 | Sep 29, 2024 |
| Osaic Holdings Inc | 0.00% | 10 | 32 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.45% | 4,103 | 13.29K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.34% | 3,146 | 10.19K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.11% | 963 | 3.12K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.10% | 954 | 3.09K | Oct 30, 2024 |